Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLC1101 Combinations in Advanced Solid Tumors With KRAS G12D Mutation
NCT06949761Phase 2Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Jun 2025
- Primary completion
- Sep 2026
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of QLC1101 in solid tumor (4 arms), sponsored by Qilu Pharmaceutical. Primary endpoint: Adverse Events. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
QLC1101
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06949761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06949761.